Fred Hutch, Seattle Cancer Care Alliance, and UW Medicine Complete Restructure of Partnership

Learn More

Hutch News

Results per Page: 20
  • 5
  • 10
  • 20
  • 50
  • 100
Red Light, Green Light: Precise cell targeting with Co-LOCKR

Red Light, Green Light: Precise cell targeting with Co-LOCKR

From the Baker, Riddell, and Pun Labs, Cancer Basic Biology, Cancer Consortium
Science Spotlight - February 21, 2022
Potential strategies for mitigating CD19 CAR T-cell associated toxicities

Potential strategies for mitigating CD19 CAR T-cell associated toxicities

From the Gauthier Group, Clinical Research Division
Science Spotlight - January 17, 2022
Vaccination after CAR-T-cell therapy

Vaccination after CAR-T-cell therapy

From the Hill group, Vaccine and Infectious Disease Division and the UW/Fred Hutch Cancer Consortium
Science Spotlight - December 20, 2021
Remodeling the tumor microenvironment for improved CAR T-cell therapy

Remodeling the tumor microenvironment for improved CAR T-cell therapy

From the Riddell and Srivastava Labs, Clinical Research Division
Science Spotlight - February 15, 2021
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel

Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel

The newly-approved CAR T-cell therapy was developed in part by Fred Hutch physician-scientists
News Releases - February 05, 2021
What’s new in breast cancer research? SABCS20 goes virtual

What’s new in breast cancer research? SABCS20 goes virtual

Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more
Hutch News - December 18, 2020
Last Modified, April 02, 2020